Genetic Specialists Should Be Consulted more for BRCA tests

Importance of Detecting BRCA1 and BRCA2 Gene Mutations in Breast Cancer Patients

Breast cancer patients with BRCA1 and BRCA2 gene mutations have an increased risk of cancer for themselves and their family members. Therefore, it is crucial to recognize these mutations to protect the family and plan for the children’s future. It is also essential to examine the genetic risk factors of the individual diagnosed with breast cancer, as they may have a higher chance of developing cancer in the other breast or ovarian.

Concerns About Scaring Breast Cancer Patients with BRCA1 and BRCA2 Gene Mutations

While discussing the issue of BRCA1 and BRCA2 gene mutations in breast cancer patients, it is essential to note that this only applies to a small subset of breast cancers. Therefore, physicians should be cautious not to cause unnecessary patient fear by providing accurate information and clarifying that this issue is only relevant to a specific group of patients.

Availability of BRCA1 and BRCA2 Genetic Testing in Our Country

Although the BRCA1 and BRCA2 genetic tests are available in many centers in our country, the detection and investigation rates of these mutations could be better in general practice. Patients often have to pay for these tests out of pocket, and the lack of availability in many hospitals means that a large group has been overlooked.

Importance of Proper Management for Breast Cancer Patients with BRCA1 and BRCA2 Gene Mutations

More than detecting the BRCA1-2 gene mutation is required; managing the patient and their family correctly is crucial. Clinical geneticists and a multidisciplinary team of healthcare professionals should be consulted, and treatment decisions should be made collaboratively. Unfortunately, our country lags in this regard, but it is a social and personal problem that scientists, government policies, and cancer centers must address.

Addressing the Deficiencies in Detecting and Managing BRCA1 and BRCA2 Gene Mutations

A recent study showed that only 5.3% of 3628 breast cancer patients tested positive for BRCA1 or BRCA2 gene mutations, and many of them were not adequately consulted by genetic clinicians. Developed countries also need to improve in this area. However, addressing these deficiencies in our country and producing solutions can help ensure that breast cancers are evaluated without any overlooked regions.